The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: Combination treatment with ANT2 shRNA and I-131

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Choi, Yun ^a   Lee, Ho Won ^b   Lee, Jaetae ^b   Jeon, Yong Hyun ^b  

^a Seoul National University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Adenine nucleotide translocase 2 (ANT2); Cytotoxic T cells (CTLs); Human sodium iodide symporter (hNIS); Radiation induced immune response; Radioiodine gene therapy; Short hairpin RNA (shRNA)

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENINE NUCLEOTIDE TRANSLOCASE 2; ADENINE NUCLEOTIDE TRANSLOCASE 2 SHORT HAIRPIN RNA; CASPASE 3; FAS ANTIGEN; IODINE 131; LACTATE DEHYDROGENASE; LUCIFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; SHORT HAIRPIN RNA; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYMATIC ASSAY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RADIOSENSITIVITY;

ADENINE NUCLEOTIDE TRANSLOCATOR 2; ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENES, MHC CLASS I; GENETIC THERAPY; IODINE RADIOISOTOPES; L-LACTATE DEHYDROGENASE; MICE; MICE, INBRED BALB C; PHENOTYPE; RADIOPHARMACEUTICALS; RNA, SMALL INTERFERING; SYMPORTERS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84875180805     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-143     Document Type: Article

References (29)

1. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 2000, 18:927-974. 10.1146/annurev.immunol.18.1.927, 10837079.
2. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003, 14(8):709-714. 10.1089/104303403765255110, 2078240, 12804135.
3. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995, 16(10):487-494. 10.1016/0167-5699(95)80033-6, 7576053.
4. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2(4):293-299. 10.1038/86297, 11276199.
5. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003, 3(9):666-675. 10.1038/nrc1167, 2305722, 12951585.
6. Dolce V, Scarcia P, Iacopetta D, Palmieri F. A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue distribution. FEBS Lett 2005, 579(3):633-637. 10.1016/j.febslet.2004.12.034, 15670820.
7. Lunardi J, Attardi G. Differential regulation of expression of the multiple ADP/ATP translocase genes in human cells. J Biol Chem 1991, 266(25):16534-16540.
8. Choi Y, Jeon YH, Jang JY, Chung JK, Kim CW. Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination. Mol Ther 2011, 19(5):979-989. 10.1038/mt.2010.235, 3098626, 21063392.
9. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002, 43(9):1188-1200.
10. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000, 80(3):1083-1105.
11. Cho JY. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther 2002, 2(4):393-402. 10.2174/1566523023347599, 12477251.
12. Chen L, Altmann A, Mier W, Eskerski H, Leotta K, Guo L, Zhu R, Haberkorn U. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006, 47(5):854-862.
13. Jeon YH, Choi Y, Yoon SO, Kim CW, Chung JK. Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy. Mol Cancer Ther 2008, 7(7):2252-2260. 10.1158/1535-7163.MCT-08-0277, 18645034.
14. Jeon YH, Choi Y, Kim HJ, Kim CW, Jeong JM, Lee DS, Chung JK. Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer 2007, 121(7):1593-1599. 10.1002/ijc.22837, 17565743.
15. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 1999, 48(7):382-385. 10.1007/s002620050590, 10501851.
16. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003, 195(3):346-355. 10.1002/jcp.10290, 12704644.
17. Bubenik J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep 2003, 10(6):2005-2008.
18. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994, 1(5):357-364. 10.1016/1074-7613(94)90066-3, 7533644.
19. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003, 170(12):6338-6347.
20. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64(21):7985-7994. 10.1158/0008-5472.CAN-04-1525, 15520206.
21. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005, 63(3):655-666. 10.1016/j.ijrobp.2005.06.032, 1489884, 16199306.
22. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11(9):3353-3362. 10.1158/1078-0432.CCR-04-2062, 15867235.
23. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811. 10.1038/35888, 9486653.
24. Hannon GJ. RNA interference. Nature 2002, 418(6894):244-251. 10.1038/418244a, 12110901.
25. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003, 63(7):1515-1519.
26. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12(5):461-466. 10.1038/sj.gt.3302425, 15616603.
27. Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 2003, 22(51):8330-8336. 10.1038/sj.onc.1206973, 14614456.
28. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A 2011, 108(2):745-750. 10.1073/pnas.1016538108, 3021044, 21187397.
29. Jang JY, Choi Y, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 2008, 10(1):R11. 10.1186/bcr1857, 2374967, 18267033.